Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs RSS 0343 (Primary)
- Indications Bronchiectasis
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 21 Jan 2025 New trial record